ACVR2A and pancreatic neoplasm: Furthermore, KRAS, EPHA7, TP53, HMGA2, GATA6, RNF43, FGFBR2, FGF23, SMARCA4, CARD11, ACVR2A, NOTCH1, and TGFR2 may serve as potential prognostic biomarkers for pancreatic cancer patients who received AG chemotherapy for first-line treatment.